Section

Technology & Innovation

Digital therapeutics, AI in recovery, telehealth, startup moves.

Eli Lilly Just Paid $3.8 Billion to Bet That Depression's Next Blockbuster Looks Like DMT

Big Pharma didn't wait for psychedelic therapy to get easy, cheap, or fully de-risked. It just bought a seat at the table — the second nine-figure-plus deal in the sector in under a year.

Eli Lilly's up-to-$3.8 billion acquisition of AtaiBeckley, weeks after FDA finalized psychedelic clinical trial guidance, signals mainstream pharma is done waiting on the sidelines of psychedelic medicine.

Jul 312 minRead

More in Technology & Innovation

19 total in this section

02Technology & InnovationJul 21

Lilly's $3.8B Psychedelic Bet Skips Past the People Who Need It Most

Eli Lilly's $3.8B AtaiBeckley acquisition is the largest Big Pharma bet on psychedelics yet — but the money is chasing a depression drug, not addiction treatment, and the medicalization it represents is a different animal from the peer-support culture that built this field.

03Technology & InnovationJul 20

Digital Health Just Raised $7.4 Billion. Addiction Treatment Barely Shows Up in the Count.

Rock Health's H1 2026 report shows $7.4B in digital health funding, concentrated in mega-deals for mental health. Addiction-specific treatment isn't named among them.

04Technology & InnovationJul 20

Arizona's Medicaid Agency Built an AI Chatbot to Find You Opioid Treatment. Will You Trust It at 2 A.M.?

AHCCCS launched a Google Gemini-powered chatbot to help Arizonans find opioid treatment providers. What it gets right, and the trust gap it still has to close.

05Technology & Innovation

Earlier in Technology & Innovation

Every piece in this section, most recent first.

Technology & Innovation

Eli Lilly Just Paid $3.8 Billion to Bet That Depression's Next Blockbuster Looks Like DMT

More in Technology & Innovation

Lilly's $3.8B Psychedelic Bet Skips Past the People Who Need It Most

Digital Health Just Raised $7.4 Billion. Addiction Treatment Barely Shows Up in the Count.

Arizona's Medicaid Agency Built an AI Chatbot to Find You Opioid Treatment. Will You Trust It at 2 A.M.?

Six Months In, Compass Pathways' Psilocybin Data Clears the Bar Lykos Couldn't

The Addiction-Tech Money Isn't Drying Up. It's Just Betting Almost Entirely on AI Now.

South Carolina Put a Naloxone Machine in a Public Building. The Data It Collects Might Matter More Than the Doses.

Earlier in Technology & Innovation

Three Different Clocks Are Running Out on Mail-Order Ketamine, and Only One of Them Is About Safety

Psilocybin Is Closer to FDA Approval Than Most People in Treatment Know. Here's the Timeline.

Relationship between attentional bias and psychological craving in methamphetamine use disorder

An AI Can Now Diagnose Addiction With 83% Accuracy. The Treatment System Still Can't Keep Up.

Ozempic for Addiction? The Science Is Catching Up to the Headlines

Virtual MOUD Doesn't Expand Access. That's Not a Failure — It's the Map.

The State of Digital Recovery Funding in 2026: Quiet Year, Selective Bets

Bicycle Health Doubles Down on Clinical Leadership — Days After PHTI Calls Virtual MOUD a Substitute, Not a Door

Smartphone-delivered contingency management is being studied. The economics already make sense.

NIH HEAL is still the biggest addiction-tech grant pool no one applies for

Pelago, Boulder, Workit, Ophelia — Who's Who in Digital Recovery

The State of Recovery Technology in 2026